Related Experiment Videos
Regression of cardiac hypertrophy: experimental and clinical results
W Motz1, M Klepzig, B E Strauer
1Department of Medicine, University of Düsseldorf, F.R.G.
Insights
Antihypertensive medications like clonidine can effectively reverse left ventricular hypertrophy, a precursor to heart failure. This study compared various treatments, finding clonidine most efficient in reducing cardiac muscle mass.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant precursor to hypertensive heart failure.
- Reversing or preventing myocardial hypertrophy is a critical therapeutic goal in managing hypertension.
- Understanding the differential effects of antihypertensive drugs on LVH is essential for effective treatment.
Purpose of the Study:
- To evaluate the efficacy of different antihypertensive treatments in regressing established hypertensive left ventricular hypertrophy.
- To compare the effects of beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, and sympathetic agents on cardiac hypertrophy and function.
- To determine the relationship between blood pressure reduction and the extent of hypertrophy reversal across various drug classes.
Main Methods:
- Experimental studies in spontaneously hypertensive rats (SHRs) treated with metoprolol, hydralazine, and nifedipine for 20-40 weeks.
- Clinical studies in patients with compensated hypertensive heart disease treated with nifedipine, enalapril, clonidine, and prazosin.
- Assessment of left ventricular hypertrophy, cardiac pumping function, and blood pressure changes.
Main Results:
- Nifedipine, prazosin, and enalapril showed equipotent effects in reducing hypertrophy relative to blood pressure reduction.
- Clonidine demonstrated the highest efficiency in inducing hypertrophy regression, with muscle mass reduction disproportionate to blood pressure lowering.
- Left ventricular pumping function improved due to afterload reduction; myocardial contractility remained unchanged.
Conclusions:
- Certain antihypertensive agents, notably clonidine, can effectively induce regression of left ventricular hypertrophy.
- The mechanism for clonidine's pronounced effect may involve reduced catecholamine levels.
- Therapeutic strategies targeting hypertensive heart disease should consider the specific impact of drugs on cardiac remodeling.
Abstract:
Since left ventricular hypertrophy is considered to be a precursor of later hypertensive heart failure, a treatment that can prevent or even reverse myocardial hypertrophy is a highly desirable goal. In order to evaluate which type of antihypertensive treatment is able to induce regression of hypertensive hypertrophy, experimental and clinical studies were performed. Experimental studies were performed in spontaneously hypertensive rats (SHRs). Left ventricular hypertrophy and pumping function were studied after antihypertensive treatment with a beta-receptor blocker (metoprolol), an arteriolar vasodilator (hydralazine), and a calcium channel blocker (nifedipine) had been instituted for a period of 20-40 weeks. Patients with hemodynamically compensated hypertensive heart disease were treated with a calcium channel blocker (nifedipine), an angiotensin-converting enzyme (ACE) inhibitor (enalapril), an antisympathetic agent (clonidine), and prazosin. Comparing the amount of blood pressure reduction with the extent of hypertrophy reversal, nifedipine, prazosin, and enalapril were equipotent, whereas clonidine was most efficient in this respect. Muscle mass was overproportionally reduced in relation to blood pressure reduction following treatment with clonidine. It is likely that this was caused by lowered catecholamine levels secondary to clonidine therapy. Left ventricular pumping function was enhanced as a result of a reduction in left ventricular afterload, whereas myocardial contractility was found to be unchanged.